# US 2002/0164687 A1 · Platelet-derived growth factor C, DNA coding therefor, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0164687 A1
- Document ID: US20020164687A1
- Status: Published application
- Kind: A1
- Application number: 09/852,209
- Filed: 2001-05-10
- Published: 2002-11-07
- Earliest claimed: 1998-09-30
- Inventors: Ulf Eriksson; Karin Aase; Xuri Li; Annica Ponten; Marko Uutela; Kari Alitalo; Arne Oestman; Carl-Henrik Heldin; Christer Betsholtz
- Web page: https://patentgrep.com/patent/US20020164687A1

## CPC

- C07K 14/49: Platelet-derived growth factor [PDGF]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2799/026: where the vector is derived from a baculovirus
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

PDGF-C, a new member of the PDGF/VEGF family of growth factors, is described, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6

### Claim 2 (depends on 1)

An isolated nucleic acid molecule according to claim 1, wherein the sequence identity is at least 90%.

### Claim 3 (depends on 1)

An isolated nucleic acid molecule according to claim 1, wherein the sequence identity is at least 95%.

### Claim 4 (depends on 1)

An isolated nucleic acid molecule according to claim 1, wherein said nucleic acid is a cDNA.

### Claim 5 (depends on 1)

An isolated nucleic acid molecule according to claim 1, wherein said nucleic acid is a mammalian polynucleotide.

### Claim 6 (depends on 5)

An isolated nucleic acid molecule according to claim 5, wherein said nucleic acid is a murine polynucleotide.

### Claim 7 (depends on 6)

An isolated nucleic acid molecule according to claim 6, comprising SEQ ID NO:6.

### Claim 8 (depends on 5)

An isolated nucleic acid molecule according to claim 5, wherein said nucleic acid is a human polynucleotide.

### Claim 9 (depends on 8)

An isolated nucleic acid molecule according to claim 8, comprising SEQ ID NO:2 or SEQ ID NO:4.

### Claim 10

An isolated nucleic acid molecule which encodes a polypeptide molecule comprising the amino acid sequence
PXCXXVXRCGGXXXCC (SEQ ID NO:1)
and having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:5, or a fragment or analog thereof having the biological activity of PDGF-C.

### Claim 11 (depends on 10)

An isolated nucleic acid molecule according to claim 10, wherein the amino acid sequence identity is at least 90%.

### Claim 12 (depends on 10)

An isolated nucleic acid molecule according to claim 10, wherein the amino acid sequence identity is at least 95%.

### Claim 13 (depends on 10)

An isolated nucleic acid molecule according to claim 10, which codes for a polypeptide which comprises a proteolytic site having the amino acid sequence RKSR or a structurally conserved amino acid sequence thereof.

### Claim 14 (depends on 1)

A vector comprising a nucleic acid according to claim 1, which nucleic acid is operably linked with a promoter sequence.

### Claim 15 (depends on 14)

A vector according to claim 14, wherein said vector is a eukaryotic vector.

### Claim 16 (depends on 14)

A vector according to claim 14, wherein said vector is a prokaryotic vector.

### Claim 17 (depends on 14)

A vector according to claim 14, wherein said vector is a plasmid.

### Claim 18 (depends on 14)

A vector according to claim 14, wherein said vector is a baculovirus vector.

### Claim 19 (depends on 1)

A method of making a vector which expresses a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or fragment or analog thereof having the biological activity of PDGF-C, said method comprising incorporating an isolated nucleic acid according to claim 1 into said vector in operatively linked relation with a promoter.

### Claim 20 (depends on 14)

A host cell transformed or transfected with a vector according to claim 14.

### Claim 21 (depends on 20)

A host cell according to claim 20, wherein said host cell is a eukaryotic cell.

### Claim 22 (depends on 20)

A host cell according to claim 20, wherein said host cell is a COS cell.

### Claim 23 (depends on 20)

A host cell according to claim 20, wherein said host cell is a prokaryotic cell.

### Claim 24 (depends on 20)

A host cell according to claim 20, wherein said host cell is a 293EBNA cell.

### Claim 25 (depends on 20)

A host cell according to claim 20, wherein said host cell is an insect cell.

### Claim 26 (depends on 1)

A host cell transformed or transfected with a vector comprising a nucleic acid sequence according to claim 1, operatively linked to a promoter, such that said host cell expresses a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF-C.

### Claim 27 (depends on 1)

A means for amplifying a polynucleotide according to claim 1 in a test sample, said means comprising at least one pair of primers complementary to a nucleic acid according to claim 1.

### Claim 28 (depends on 1)

A means for amplifying a polynucleotide according to claim 1 in a test sample, said means comprising a polymerase and at least one pair of primers complementary to a nucleic acid according to claim 1, for amplifying the polynucleotide by polymerase chain reaction in order to facilitate a sequence comparison of the polynucleotide with the nucleic acid according to claim 1.

### Claim 29

An antibody specifically reactive with a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF-C, or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.

### Claim 30 (depends on 29)

An antibody according to claim 29, wherein said antibody is a polyclonal antibody.

### Claim 31 (depends on 29)

An antibody according to claim 29, wherein said antibody is a monoclonal antibody or a F(ab′)2, F(ab′), F(ab) fragment or chimeric antibody.

### Claim 32 (depends on 29)

An antibody according to claim 29, wherein said antibody is labeled with a detectable label.

### Claim 33 (depends on 32)

An antibody according to claim 32, wherein said detectable label is radioactive isotope.

### Claim 34 (depends on 31)

An antibody according to claim 31, wherein said monoclonal antibody is a humanized antibody.

### Claim 35

A method of making a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF-C, or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, said method comprising the steps of:
culturing a host cell transformed or transfected with a vector comprising a polynucleotide encoding said polypeptide operably associated with a promoter sequence such that the nucleic acid sequence encoding said polypeptide is expressed; and
isolating said polypeptide from said host cell or from a growth medium in which said host cell is cultured.

### Claim 36

A method of stimulating growth of connective tissue or wound healing in a mammal, said method comprising administering to said mammal an effective growth stimulating amount of a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF-C, or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.

### Claim 37

A method of making a vector which expresses a polypeptide comprising an amino acid sequence having at least .85% identity with at least amino acid residues 230 to 345 of SEQ ID NO:3 or of SEQ ID NO:7, said method comprising incorporating an isolated nucleic acid molecule encoding said amino acid residues into said vector in operatively linked relation with a promoter.

### Claim 38 (depends on 37)

A method for producing an active truncated form of PDGF-C, comprising the step of expressing an expression vector comprising a polypeptide-encoding polynucleotide as claimed in claim 37.

### Claim 39

A method for regulating receptor-binding specificity of PDGF-C, comprising the steps of expressing an expression vector comprising a polynucleotide encoding a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF-C, or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, and supplying a proteolytic amount of at least one enzyme for processing the expressed polypeptide to generate the active truncated form of PDGF-C.

### Claim 40

A method for selectively activating a polypeptide having a growth factor activity comprising the step expressing an expression vector comprising a polynucleotide encoding a polypeptide having a growth factor activity, a CUB domain and a proteolytic site between the polypeptide and the CUB domain, and supplying a proteolytic amount of at least one enzyme for processing the expressed polypeptide to generate the active polypeptide having a growth factor activity.

### Claim 41

An isolated heterodimer comprising an active monomer of VEGF, VEGF-B, VEGF-C, VEGF-D, PDGF-C, PDGF-A, PDGF-B or PlGF and an active monomer of PDGF-C linked to a CUB domain.

### Claim 42 (depends on 41)

An isolated heterodimer according to claim 41, further comprising a proteolytic site between the active monomer and the CUB domain linkage.

### Claim 43

An isolated heterodimer comprising an active monomer of PDGF-C and an activated monomer of VEGF, VEGF-B, VEGF-C, VEGF-D, PDGF-C, PDGF-A, PDGF-B or PlGF linked to a CUB domain.

### Claim 44 (depends on 43)

An isolated heterodimer according to claim 43, further comprising a proteolytic site between the activated monomer and the CUB domain linkage.

### Claim 45

An isolated polynucleotide, comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, and which encodes a sequence of amino acids comprising SEQ ID NO:1.

### Claim 46

A method of promoting fibroblast mitogenesis in a mammal, comprising the step of administering to said mammal an effective fibroblast mitogenesis promoting amount of a polypeptide comprising an amino acid sequence having at least 85% identity with at least amino acid residues 230 to 345 of SEQ ID NO:3 or of SEQ ID NO:7.

### Claim 47

A method of promoting fibroblast mitogenesis in a mammal, comprising administering to said mammal an effective frbroblast mitogenesis promoting amount of a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF-C, or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.

### Claim 48

A method of inducing PDGF alpah receptor activation, comprising the step of adding a PDGF alpha-receptor stimulating amount of a polypeptide comprising an amino acid sequence having at least 85% identity with at least amino acid residues 230 to 345 of SEQ ID NO:3 or of SEQ ID NO:7.

### Claim 49

A method of inducing PDGF alpha receptor activation, comprising the step of adding a PDGF alpha-receptor stimulating amount of a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF-C, or a polypeptide produced by expression of a polynucleotide comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or of a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6.

### Claim 50

A method of inhibiting tumor growth of a tumor expressing PDGF-C in a mammal, comprising administering to said mammal a PDGF-C inhibiting amount of a PDGF-C antagonist.

### Claim 51

A method of identifying specific types of human tumors, comprising the step of taking a sample of the tumor and testing for the expression of PDGF-C.

### Claim 52 (depends on 51)

The method of claim 51, wherein the specific types of tumors are selected from the group consisting of choriocarcinoma, Wilms tumor, megakaryoblastic leukemia, lung carcinoma and erythroleukemia.

### Claim 53

A method for identifying an PDGF-C antagonist comprising:
admixing a substantially purified preparation of an activated truncated form of PDGF-C; and
monitoring, by any suitable means, an inhibition in the biological activity of PDGF-C.

### Claim 54

A method for identifying an PDGF-C antagonist comprising:
admixing a substantially purified preparation of an full-length PDGF-C with a test agent; and
monitoring, by any suitable means, an inhibition in the cleavage of the CUB domain from PDGF-C.

### Claim 55

A method for producing an activated truncated form of PDGF-C, comprising the steps of:
expressing an expression vector comprising a polynucleotide encoding a polypeptide comprising an amino acid sequence having at least 85% identity with SEQ ID NO:3 or SEQ ID NO:7, or a fragment or analog thereof having the biological activity of PDGF-C, or comprising a polynucleotide comprising a polynucleotide sequence having at least 85% identity with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, or a polynucleotide which hybridizes under stringent conditions with SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, and
supplying a proteolytic amount of at least one enzyme for processing the expressed polypeptide to generate the activated truncated form of PDGF-C.

### Claim 56

A method of inhibiting tissue remodeling during invasion of tumor cells into a normal population of cells, comprising administering to said mammal a PDGF-C inhibiting amount of a PDGF-C antagonist.

### Claim 57

A method of treating fibrotic conditions in a mammal in need a such treatment, comprising administering to said mammal a PDGF-C inhibiting amount of a PDGF-C antagonist.

### Claim 58 (depends on 57)

A method of claim 57, wherein the fibrotic conditions are found in the lung, kidney or liver.

### Claim 59

A method of promoting angiogenesis in a bird or mammal, said method comprising administering to said bird or mammal an effective angiogenesis promoting amount of a polypeptide comprising a sequence of amino acids having at least 85% identity with at least amino acid residues 230 to 345 of SEQ ID NO:3 or of SEQ ID NO:7.

### Claim 60 (depends on 59)

A method according to claim 59, wherein said polypeptide is administered in the form of a dimer.
